Jesse Allen

Jesse Allen

Auto-generated profile, based on publicly available information

Jesse Allen

Paul L. Foster School of Medicine, Department of Medical Education, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EHEthan Heh
Ethan Heh
JAJesse Allen
Jesse Allen
FRFabiola Ramirez
Fabiola Ramirez
DLDaniel Lovasz
Daniel Lovasz
LFLorena Fernandez
Lorena Fernandez
JCJessica A Chacon
Jessica A Chacon
Drug conjugates have become a significant focus of research in the field of targeted medicine for cancer treatments. Peptide-drug conjugates (PDCs), a subset of drug conjugates, are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and linkers that connect the payload to the peptide. PDCs are further broken down into cell-penetrating peptides (CPPs) and cell-targeting peptides (CTPs), each having their own differences in the delivery of cytotoxic payloads. Generally, PDCs as compared to other drug conjugates—like antibody-drug conjugates (ADCs)—have advantages in tumor penetration, ease of synthesis and cost, and reduced off-target effects. Further, as compared to traditional cancer treatments (e.g., chemotherapy and radiation), PDCs have higher specificity for the target cancer with generally less toxic side effects in smaller doses. However, PDCs can have disadvantages such as poor stability and rapid renal clearance due to their smaller size and limited oral bioavailability due to digestion of its peptide structure. Some of these challenges can be overcome with modifications, and despite drawbacks, the intrinsic small size of PDCs with high target specificity still makes them an attractive area of research for cancer treatments.

1 January 2023 in Digital Health
Verified
Journal Article
Open access
SJSarah Johnson
Sarah Johnson
JAJesse Allen
Jesse Allen
LFLorena Fernandez
Lorena Fernandez
VGVeeravenkata Garikiparthy
Veeravenkata Garikiparthy
LRLaura Renovato
Laura Renovato
JCJessica A Chacon
Jessica A Chacon
El Paso, Texas, like many communities along the United States/Mexico border, suffers from a lack of access to many social determinants of health, especially in low-income neighborhoods. These long-standing problems have only been exacerbated by the COVID-19 pandemic. The Texas Tech University Health Sciences Center El Paso Health Education and Awareness Team (EP-HEAT) is an organization that was established with a focus on disseminating health information to the community. EP-HEAT received funding from Microsoft Corporation to facilitate technology education workshops for underserved populations. These workshops were held in English and Spanish and attempted to improve social determinants of health in the community which can be negatively exacerbated by a lack of digital inclusion. Community members who attended workshops completed a LinkedIn Learning Path, or both were offered an anonymous post-course survey with a mixed method questionnaire on how their knowledge of basic technology or job skills was improved by engaging with the provided workshops and learning paths. Overall, 80% of community members who participated in the workshops reported learning a new skill, and 91% of participants who started a LinkedIn Learning Path were able to finish. The workshops were well received by the community and highlighted the potential for these programs to enhance digital skills and upward workforce mobility.

Verified
Journal Article
Open access
PDF file
Joshua LaraJoshua Lara
Joshua Lara
ABAlfonso Enrique Bencomo-Alvarez
Alfonso Enrique Bencomo-Alvarez
MGMayra Alejandra Gonzalez
Mayra Alejandra Gonzalez
IOIdaly M. Olivas
Idaly M. Olivas
JYJames E. Young
James E. Young
Anna EiringAnna Eiring
Anna Eiring
26S proteasome non-ATPase subunits 1 (PSMD1) and 3 (PSMD3) were recently identified as prognostic biomarkers and potential therapeutic targets in chronic myeloid leukemia (CML) and multiple solid tumors. In the present study, we analyzed the expression of 19S proteasome subunits in acute myeloid leukemia (AML) patients with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene and assessed their impact on overall survival (OS). High levels of PSMD3 but not PSMD1 expression correlated with a worse OS in FLT3-mutated AML. Consistent with an oncogenic role for PSMD3 in AML, shRNA-mediated PSMD3 knockdown impaired colony formation of FLT3+ AML cell lines, which correlated with increased OS in xenograft models. While PSMD3 regulated nuclear factor-kappa B (NF-κB) transcriptional activity in CML, we did not observe similar effects in FLT3+ AML cells. Rather, proteomics analyses suggested a role for PSMD3 in neutrophil degranulation and energy metabolism. Finally, we identified additional PSMD subunits that are upregulated in AML patients with mutated versus wild-type FLT3, which correlated with worse outcomes. These findings suggest that different components of the 19S regulatory complex of the 26S proteasome can have indications for OS and may serve as prognostic biomarkers in AML and other types of cancers.

15 November 2022 in Blood
Verified
Journal Article
Open access
JLJoshua J. Lara
Joshua J. Lara
ABAlfonso E. Bencomo
Alfonso E. Bencomo
MGMayra A. Gonzalez
Mayra A. Gonzalez
IOIdaly M. Olivas
Idaly M. Olivas
JLJose L. Lopez
Jose L. Lopez
Anna EiringAnna Eiring
Anna Eiring
Introduction. Acute myeloid leukemia (AML) is a heterogeneous leukemic disease that results from abnormal stem cells in the bone marrow. Despite initial high re